Virax Biolabs Group EBIT

The latest EBIT for VRAX is $-13M as of March 2026. That compares with $-18M in the prior-year period — up 28.5% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside Virax Biolabs Group's historical trend and sector peers before judging valuation or financial health.

Over the past year, VRAX's EBIT moved from $-18M to $-13M — a 28.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Virax Biolabs Group's operating scale or balance-sheet position.

Against its sector companies, VRAX currently prints $-13M for EBIT, while the sector average sits near $-63M. That is roughly 79.9% above the sector mean. Large gaps often invite a closer look at Virax Biolabs Group's growth, margins, and balance sheet.

A EBIT figure of $-13M for VRAX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting VRAX's EBIT ($-13M), review year-over-year change from $-18M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.